Fig. 8: Schematic of how BM-MSCs may decrease liver fibrosis by targeting Ly6Chi/lo macrophages through activating the cytokine-paracrine and apoptotic pathways. | Cell Death Discovery

Fig. 8: Schematic of how BM-MSCs may decrease liver fibrosis by targeting Ly6Chi/lo macrophages through activating the cytokine-paracrine and apoptotic pathways.

From: Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6Chi/lo macrophages through activating the cytokine-paracrine and apoptotic pathways

Fig. 8: Schematic of how BM-MSCs may decrease liver fibrosis by targeting Ly6Chi/lo macrophages through activating the cytokine-paracrine and apoptotic pathways.The alternative text for this image may have been generated using AI.

CCL2 secreted by the fibrotic liver promoted the recruitment of Ly6Chi monocytes from bone marrow to the liver. BM-MSC transplantation promoted the conversion of Ly6Chi to Ly6Clo macrophages by secreting cytokines IL4 and IL10, which decreased the activation of HSCs. Meanwhile, BM-MSCs experienced severe apoptosis and produced substantial apoptotic bodies, which were engulfed by Ly6Clo macrophages, leading to MMP12 release and accelerated extracellular matrix (ECM) degradation in CCL4-induced liver fibrosis.

Back to article page